Research paper
Vitamin D treatment in primary hyperparathyroidism: a randomized placebo controlled trial.
Study answer
What this study found
High-dose vitamin D3 was safe and improved vitamin D status and PTH control in patients with primary hyperparathyroidism. In the vitamin D group, 25OHD rose from 50.2 to 94.2 nmol/L preoperatively (P < .001), PTH fell by 17% with an absolute difference of 2.4 ± 1.2 pmol/L, and 1,25(OH)2D increased from 98 to 127 pmol/L (30%, P = .008). Bone resorption improved preoperatively, with CTx decreasing 22% (P < .005) and lumbar spine BMD increasing 2.5% (P = .01) versus placebo; after surgery, PTH remained lower in the vitamin D group (P = .04), while calcium levels and renal function were…
- Study & population
- Single-center, investigator-initiated, double-blind, randomized, placebo-controlled, parallel-group trial at Aarhus University Hospital in Denmark.
- Intervention
- Vitamin D3 (cholecalciferol) was given orally at 70 g (2800 IU) daily for 52 weeks, covering 6 months before and 6 months after parathyroidectomy.
- Key limitation
- The trial was small, with only 20 participants per active arm analyzed/completed, and it was conducted at a single center in Denmark, limiting generalizability.
View source
Open PDFOriginal abstract
CONTEXT Low 25-hydroxyvitamin D levels are common in patients with primary hyperparathyroidism (PHPT) and associated with higher PTH levels and hungry bone syndrome after parathyroidectomy (PTX). However, concerns have been raised about the safety of…